XML 41 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Statements of Cash Flows (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:    
Net income (loss) $ 1,464,930 $ (870,306)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation expense 18,176 18,816
Amortization of patents 77,947 76,317
Amortization of debt discount 0.00 3,065
Common stock and options issued for compensation, consulting, and vendor services 1,077,213 673,691
Increase in accrued interest for notes payable   87,016
Bad debt reversal (308,350) (207,650)
Loss on sale/disposal of equipment   1,604
Loss on Earnings from Medical Joint Venture 924,363 171,016
Loss on Earnings from Education Joint Venture 7,918  
Gain on Dilutive Effect on Medical Joint Venture (1,363,650)  
Write-off of Investment in German Distributor   76,319
Changes in operating assets and liabilities:    
(Increase) Decrease in accounts receivable (126,323) 525,182
(Increase) Decrease in inventories (683,091) 151,933
Decrease to advances on contracts 519,094 579,060
Decrease to prepaid expenses and other current assets 88,610 65,119
(Increase) Decrease in other assets (5,600) 20,502
(Decrease) in accounts payable (316,226) (1,594,937)
(Decrease) Increase in accrued expenses (116,275) 173,535
Net cash provided by (used in) operating activities 1,258,736 (49,718)
Cash flows from investing activities:    
Investment in Education Joint Venture (50,000)  
Investment in Medical Joint Venture (484,828)  
Purchases of property and equipment (5,539) (4,735)
Payments for patent rights (21,020) (26,622)
Net cash used in investing activities (561,387) (31,357)
Cash flows from financing activities:    
Proceeds from exercise of stock options 34,600  
Proceeds from the sale of common stock 200,000 150,000
Proceeds from related party loan 50,000  
Net cash provided by financing activities 284,600 150,000
NET INCREASE IN CASH AND CASH EQUIVALENTS 981,949 68,925
Cash and cash equivalents at beginning of year 165,249 96,324
Cash and cash equivalents at end of year 1,147,198 165,249
Supplemental disclosure of non cash investing and financing activities:    
Shares issued to directors for the exercise of stock options 34,600  
Shares issued to directors for compensation 45,000 45,000
Shares issued for conversion of notes payable and accrued interest 860,081  
Shares issued to employees in lieu of cash compensation 47,500 43,125
Shares issued to settle accounts payable 400,000 217,415
Gain on Dilutive Effect on Medical Joint Venture stock issuance $ 1,363,650